NCT02173899已完成4 期
A Study to Evaluate the Immunogenicity and Safety of 2 Doses of Live Attenuated Varicella Vaccine
适应症
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 716
- 试验地点
- 1
- 主要终点
- Seroconversion rate and GMTs for live attenuated varicella vaccine
研究概览
简要总结
The purpose of this study is to observe the occurrence of adverse events, seroconversion rate and geometric mean titres(GMTs) of 2 doses of live attenuated varicella vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 7 Years（Child）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Parent/legal acceptable representative is willing and able to understand the protocol requirements and provide informed consent
- •Participant is aged ≥ 1 year to ≤ 7 years
- •Participant without preventive inoculation of varicella vaccine and previous history of chickenpox and zoster
- •Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures
- •Body temperature ≤ 37.5℃
排除标准
- •Known allergy to any constituent of the vaccine
- •Known acute illness, severe chronic disease, acute exacerbation of chronic disease and fever
- •Known or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth
- •Reported the history of allergies, convulsions, epilepsy, mental illness and brain disease and clear serious systemic reaction
- •Failed to the Expanded Programme on Immunization(EPI)
- •Receipt of any vaccine in the 4 weeks preceding the trial vaccination
- •Plan to receive any vaccine in the 4 weeks following the trial vaccination
- •Known bleeding disorder
- •Receipt of whole blood, blood plasma or immunoglobulin in the 5 months preceding the trial vaccination
- •Reported the history of acute illness had need systemic antibiotics or antiviral treatment of infections in the 7 days preceding the trial vaccination
- •An acute illness with or without fever (temperature ≥ 38.0℃) in the 3 days preceding enrollment in the trial
- •Participation in any other interventional clinical trial
- •Any condition which, in the opinion of the investigator, would pose a health risk to the subject or interfere with the vaccine
结局指标
主要结局
Seroconversion rate and GMTs for live attenuated varicella vaccine
时间窗: 35-42 days after the second dose
次要结局
- Occurrence of adverse events(within 30 days after the second dose)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
4 期
Immunogenicity and Safety Study of 2 Doses of Live Attenuated Varicella VaccineChickenpoxNCT01817270Changchun Keygen Biological Products Co., Ltd.368
已完成
4 期
Immunogenicity and Safety of Live Attenuated Varicella Vaccine Combined With Live Attenuated JE VaccineJapanese EncephalitisChickenpoxNCT01815073Changchun Keygen Biological Products Co., Ltd.497
已完成
3 期
Safety Study of Herpes Simplex Vaccine in HSV Seronegative and Seropositive Females Between 10 and 17 Years OldHerpes SimplexNCT00224484GlaxoSmithKline5,960
已完成
3 期
Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and OlderInfluenzaNCT00979602GlaxoSmithKline4,048
已完成
1 期
A Study of Modified mRNA Vaccines in Healthy AdultsSARS-CoV-2Seasonal InfluenzaRespiratory Syncytial VirusCytomegalovirusNCT05397223ModernaTX, Inc.308